Key result
Totally transthoracic echocardiography-guided transcatheter device closure of atrial septal defect in pregnant women achieved a 100% immediate complete closure rate with no serious complications.
Why the study?
Little study has focused on whether transcatheter device closure of atrial septal defect can be guided totally by transthoracic echocardiography, particularly in pregnant women.
Does totally TTE guided transcatheter device closure of ASD provide safe and effective treatment in pregnant women?
Observational (n=6)
No
Does totally TTE guided transcatheter device closure of ASD provide safe and effective treatment in pregnant women?
Totally TTE-guided transcatheter ASD closure without fluoroscopy is feasible, safe, and effective in pregnant women, avoiding radiation exposure.
Answers are grounded in this paper and cite their sources.
May support radiation-free ASD closure in pregnancy; leaves open validation in prospective studies.
BACKGROUND: Transcatheter device closure of atrial septal defect (ASD) guided by fluoroscopy and/or transesophageal echocardiography is a mature technology. Little study has focused on whether the technology can be guided totally by transthoracic echocardiography (TTE), even in pregnant women with ASD. AIM: To evaluate the safety and efficacy of totally TTE guided transcatheter device closure of ASD in pregnant women. METHODS: Six pregnant women (gestational age 20-26 wk) with ASD underwent transcatheter device closure totally guided by TTE at our cardiac center from January 2015 to August 2017. A routine transcatheter procedure without fluoroscopy or intubation and a domestic occluder were used in this study. RESULTS: All patients had successful closure with good clinical results, and the overall immediate complete closure rate was 100%. The size of the occluder deployed ranged from 20 to 32 mm (26.7 ± 4.3 mm), the procedure time ranged from 30 to 50 min (41.7 ± 7.5 min), and the length of hospital stay was 2-3 d (mean 2.2 ± 0.4 d). There were no serious cardiovascular related complications, and transient arrhythmias occurred in one patient during the procedure. During the follow-up period (3 mo to 2 years), no occluder dislodgement, residual fistulas, or thromboses occurred. All of the patients underwent vaginal delivery between 36 and 38 wk of gestation. CONCLUSION: Totally TTE guided transcatheter device closure of ASD in pregnant women may be safe and effective.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2019) conducted an observational in Atrial septal defect (n=6). Totally transthoracic echocardiography (TTE) guided transcatheter device closure was evaluated on Immediate complete closure rate. Totally transthoracic echocardiography-guided transcatheter device closure of atrial septal defect in pregnant women achieved a 100% immediate complete closure rate with no serious complications.
Synapse has enriched 10 related papers. Consider them for comparative context: